Proceedings of the National Academy of Sciences · 1998 · 91 citations · 37 references
MedicineEndocrinologyOncologyCancer PharmacologyEndocrine OncologyMolecular OncologyGrowth Factor SignalingHormonal Cancer TherapyHormonal TherapyHormone SignalingHormone-secreting TumorsProstate CancerAntineoplastic HormonesProstate Cancer Hormonal TherapyProstate Growth RegulationReverse Transcription Polymerase Chain Reaction (Rt-pcr)Therapy-induced Growth InhibitionTumor Growth DynamicsTumor Growth Rate
Insulin-like growth factors I and II (IGF-I and -II) are potent mitogens for various cancers, including carcinoma of the prostate. In several experimental cancers, treatment with antagonists of growth hormone-releasing hormone (GH-RH) produces a reduction in IGF-I and -II, concomitant to inhibition of tumor growth. To investigate the mechanisms involved, we treated male nude mice bearing xenografts of DU-145 human androgen-independent prostate cancer for 8 weeks with potent GH-RH antagonist MZ-5-156 at a dose of 20 microg/animal s.c. twice a day. Tumor growth, serum and tumor levels of IGF-I and -II, and the mRNA expression of IGF-I and -II in tumors were evaluated. After 8 weeks of therapy, final volume and weight of DU-145 tumors in mice treated with MZ-5-156 were significantly (P < 0.01) decreased compared with controls, and serum IGF-I showed a significant reduction. Treatment of nude mice bearing DU-145 xenografts with MZ-5-156 also significantly (P < 0.01) diminished by 77% the levels of IGF-II in tumor tissue compared with controls, but did not affect the concentration of IGF-I. Reverse transcription-PCR analyses revealed a high expression of IGF-II mRNA in DU-145 tumors. Treatment with GH-RH antagonist MZ-5-156 decreased the expression of IGF-II mRNA by 58% (P < 0.01) as compared with controls. Our work suggests that GH-RH antagonist MZ-5-156 may inhibit the growth of DU-145 human androgen-independent prostate cancers through a reduction in the production and mRNA expression of IGF-II by the tumor tissue. These findings extend our observations on the mechanism of action of GH-RH antagonists and may explain how GH-RH antagonists inhibit tumor growth.
37
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
June M. Chan, Meir J. Stampfer, Edward L. Giovannucci et al. · Science · 1998 · 2K citations
Medicine, Endocrinology, Urology +16
T. Tong, S. Bolden, Phyllis A. Wingo · CA A Cancer Journal for Clinicians · 1996 · 1.8K citations · Full text
Medicine, Biostatistics, Oncology +17
Isolation of a human prostate carcinoma cell line (DU 145)
Kenneth R. Stone, Don D. Mickey, Heidi Wunderli et al. · International Journal of Cancer · 1978 · 1.2K citations
William H. Daughaday, Ida K. Mariz, Sandra L. Blethen · The Journal of Clinical Endocrinology & Metabolism · 1980 · 745 citations